Evidence map›Paper›PMID 36028903›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma.

Yanliang Wang, Yu Chen Feng, Yujin Gan, Liu Teng, Li Wang, Ting La, Peilin Wang, Yue Gu, Lei Yan, Na Li and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. LINC02167 stabilizes KSR1 mRNA in an mJournal of experimental & clinical cancer research : CR · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  18. Enhancing mHeliyon · 2024
    Article
  19. The mMolecular cancer · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Yanliang Wang *Department of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Yu Chen Feng *School of Medicine and Public Health, The University of Newcastle, Newcastle, Australia.
Yujin GanDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Liu TengDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Li WangSchool of Basic Medicine Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, China.
Ting LaTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Long Non-Coding RNA and Cancer Metabolism, Henan International Joint Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Peilin WangTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Long Non-Coding RNA and Cancer Metabolism, Henan International Joint Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Yue GuDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Lei YanDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Na LiDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Lina ZhangDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Limeng WangDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Rick F ThorneTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Long Non-Coding RNA and Cancer Metabolism, Henan International Joint Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China.
Xu Dong ZhangTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Long Non-Coding RNA and Cancer Metabolism, Henan International Joint Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China. Xu.Zhang@newcastle.edu.au.
Huixia CaoDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China. huixiacao310@126.com.
Feng-Min ShaoDepartment of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China. fengminshao@126.com.
Zhengzhou University · CNHenan Provincial People's Hospital · CNUniversity of Newcastle Australia · AU

Funding

Cancer Council NSW RG20-01Cancer Council NSW RG21-10Cancer Institute NSW 2021/ECF1359Henan Provincial Science and Technology Research Project 201300310700Henan Provincial Science and Technology Research Project 222102310088Henan Provincial Science and Technology Research Project 222102520014National Natural Science Foundation of China 81700578National Natural Science Foundation of China 81770725National Natural Science Foundation of China 82100731National Natural Science Foundation of China 82103292Natural Science Foundation of Henan Province 202300410401
6 · The paper itself

Abstract

backgroundDistant metastasis is the major cause of clear cell renal cell carcinoma (ccRCC)-associated mortality. However, molecular mechanisms involved in ccRCC metastasis remain to be fully understood. With the increasing appreciation of the role of long non-coding RNAs (lncRNAs) in cancer development, progression, and treatment resistance, the list of aberrantly expressed lncRNAs contributing to ccRCC pathogenesis is expanding rapidly.

methodsBioinformatics analysis was carried out to interrogate publicly available ccRCC datasets. In situ hybridization and qRT-PCR assays were used to test lncRNA expression in human ccRCC tissues and cell lines, respectively. Chromatin immunoprecipitation and luciferase reporter assays were used to examine transcriptional regulation of gene expression. Wound healing as well as transwell migration and invasion assays were employed to monitor ccRCC cell migration and invasion in vitro. ccRCC metastasis was also examined using mouse models in vivo. RNA pulldown and RNA immunoprecipitation were performed to test RNA-protein associations, whereas RNA-RNA interactions were tested using domain-specific chromatin isolation by RNA purification.

resultsMILIP expression was upregulated in metastatic compared with primary ccRCC tissues. The increased MILIP expression in metastatic ccRCC cells was driven by the transcription factor AP-2 gamma (TFAP2C). Knockdown of MILIP diminished the potential of ccRCC cell migration and invasion in vitro and reduced the formation of ccRCC metastatic lesions in vivo. The effect of MILIP on ccRCC cells was associated with alterations in the expression of epithelial-to-mesenchymal transition (EMT) hallmark genes. Mechanistically, MILIP formed an RNA-RNA duplex with the snail family transcriptional repressor 1 (Snai1) mRNA and bound to Y-box binding protein 1 (YBX1). This promoted the association between the YBX1 protein and the Snai1 mRNA, leading to increased translation of the latter. Snai1 in turn played an important role in MILIP-driven ccRCC metastasis.

conclusionsThe TFAP2C-responsive lncRNA MILIP drives ccRCC metastasis. Targeting MILIP may thus represent a potential avenue for ccRCC treatment.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRNA, Long NoncodingSnail Family Transcription FactorsY-Box-Binding Protein 1AnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceRNA, MessengerRNA, Long NoncodingRNA, MessengerSNAI1 protein, humanSnail Family Transcription FactorsY-Box-Binding Protein 1YBX1 protein, humanClear cell renal cell carcinomaLong non-coding RNAMILIPSnai1YBX1

Identifiers

PMID36028903
PMCPMC9414127
OpenAlexW4293225083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.